Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.
DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.
T cell-based cancer immunotherapy has achieved great success in the clinic; however, only a small fraction of patients respond to this therapy. Strategies to specifically and safely augment anticancer activity through controlled delivery of T cell supporting factors or drugs for combination therapy remain of high interest. Here, we devised a T cell force-responsive system for selective delivery of anticancer drugs using a mesoporous silica microparticle capped with a DNA force sensor. Upon T cell receptor (TCR) triggering, T cells exerted synaptic forces, a unique biophysical stimulus, to rupture the force-sensitive DNA gatekeepers on the mesopores leading to rapid drug release. Our results demonstrated that this cellular force-responsive system specifically released anticancer drugs in a T cell force-dependent manner and significantly enhanced cancer cell killing in vitro and in vivo. This work opens a new horizon toward designing next-generation drug delivery systems in response to signaling-specific cellular forces.
Douglas Hanahan, Krisztian Homicsko, Morgane Marie Lecointre, Jeremy Gilles Louis Guillot, Marjorie Gabrielle Marie Cayatte, Dilara Selin Ozdoganlar